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Summary
Background Vitamin A deﬁ ciency is a risk factor for blindness and for mortality from measles and diarrhoea in 
children aged 6–59 months. We aimed to estimate trends in the prevalence of vitamin A deﬁ ciency between 1991 and 
2013 and its mortality burden in low-income and middle-income countries.
Methods We collated 134 population-representative data sources from 83 countries with measured serum retinol 
concentration data. We used a Bayesian hierarchical model to estimate the prevalence of vitamin A deﬁ ciency, deﬁ ned 
as a serum retinol concentration lower than 0·70 μmol/L. We estimated the relative risks (RRs) for the eﬀ ects of vitamin 
A deﬁ ciency on mortality from measles and diarrhoea by pooling eﬀ ect sizes from randomised trials of vitamin A 
supplementation. We used information about prevalences of deﬁ ciency, RRs, and number of cause-speciﬁ c child deaths 
to estimate deaths attributable to vitamin A deﬁ ciency. All analyses included a systematic quantiﬁ cation of uncertainty.
Findings In 1991, 39% (95% credible interval 27–52) of children aged 6–59 months in low-income and middle-income 
countries were vitamin A deﬁ cient. In 2013, the prevalence of deﬁ ciency was 29% (17–42; posterior probability [PP] of 
being a true decline=0·81). Vitamin A deﬁ ciency signiﬁ cantly declined in east and southeast Asia and Oceania from 42% 
(19–70) to 6% (1–16; PP>0·99); a decline in Latin America and the Caribbean from 21% (11–33) to 11% (4–23; PP=0·89) 
also occurred. In 2013, the prevalence of deﬁ ciency was highest in sub-Saharan Africa (48%; 25–75) and south Asia (44%; 
13–79). 94 500 (54 200–146 800) deaths from diarrhoea and 11 200 (4300–20 500) deaths from measles were attributable to 
vitamin A deﬁ ciency in 2013, which accounted for 1·7% (1·0–2·6) of all deaths in children younger than 5 years in low-
income and middle-income countries. More than 95% of these deaths occurred in sub-Saharan Africa and south Asia.
Interpretation Vitamin A deﬁ ciency remains prevalent in south Asia and sub-Saharan Africa. Deaths attributable to 
this deﬁ ciency have decreased over time worldwide, and have been almost eliminated in regions other than south 
Asia and sub-Saharan Africa. This new evidence for both prevalence and absolute burden of vitamin A deﬁ ciency 
should be used to reconsider, and possibly revise, the list of priority countries for high-dose vitamin A supplementation 
such that a country’s priority status takes into account both the prevalence of deﬁ ciency and the expected mortality 
beneﬁ ts of supplementation.
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Introduction
Vitamin A deﬁ ciency causes xerophthalmia, a range of eye 
conditions from night blindness to more severe clinical 
outcomes such as keratomalacia and corneal scars, and 
permanent blindness. Vitamin A deﬁ ciency is also 
associated with an increased risk of mortality from measles 
and diarrhoea in children.1–3 WHO recommends vitamin A 
supplementation with a dose of 30 mg retinol equivalents 
in infants aged 6–11 months and 60 mg retinol equivalents 
at least twice a year in young children aged 12–59 months 
living in settings where vitamin A deﬁ ciency is a public 
health problem,4 with up to 100 countries implementing 
this guidance.5 Vitamin A supplementation is also included 
in international responses to child and maternal 
undernutrition—eg, in the Scaling-Up Nutrition initiative.6
To plan for these programmes, information is needed 
about the magnitude of vitamin A deﬁ ciency in diﬀ erent 
regions and countries and how it has changed over time 
while changes in general nutrition of the population 
have occurred. WHO has compiled data for vitamin A 
deﬁ ciency by country and used the data to make estimates 
of vitamin A deﬁ ciency worldwide and by region, at 
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speciﬁ c points in time.7,8 Other researchers have also 
reported change across repeated surveys.9–11 Researchers, 
together with the UN Standing Committee on Nutrition, 
used a regression with time-varying covariates to analyse 
how vitamin A deﬁ ciency has changed in world regions.9,11
Some studies have also estimated deaths attributable to 
vitamin A deﬁ ciency at one or two timepoints using data 
for prevalence and relative risks (RRs) for the eﬀ ects of 
vitamin A deﬁ ciency on cause-speciﬁ c mortality.12–16 In 
the past few decades, child mortality has decreased 
substantially in most countries,17 with lower mortality 
from diarrhoea, an important contributor to this decline.18 
Mortality from measles, another disease aﬀ ected by 
vitamin A deﬁ ciency, has also decreased faster than 
overall child mortality.18 Therefore, mortality attributable 
to vitamin A deﬁ ciency might have changed above and 
beyond what is due to a change in the prevalence of 
deﬁ ciency. We aimed to estimate trends in the prevalence 
of vitamin A deﬁ ciency and the number of child deaths 
attributable to this risk factor during a period in which 
both the prevalence of deﬁ ciency and cause-speciﬁ c child 
mortality are likely to have changed.
Methods
Study design
Our aim was to estimate the prevalence of vitamin A 
deﬁ ciency and the number of child deaths attributed to 
vitamin A deﬁ ciency for every low-income and middle-
income country over time. Our analysis had three 
components: ﬁ rst, we gathered data for the prevalence of 
vitamin A deﬁ ciency and the RRs for the association 
between vitamin A deﬁ ciency and mortality. Second, we 
synthesised these data to generate estimates of trends in 
vitamin A deﬁ ciency prevalence, in children aged 
6–59 months, and pooled RRs for its eﬀ ects on speciﬁ c 
causes of child death. Third, we calculated the number of 
deaths attributable to vitamin A deﬁ ciency. We did all 
calculations by country for 138 low-income and middle-
income countries; we grouped countries into ﬁ ve regions 
for modelling and presentation (appendix). 
Data sources
Our data search and access strategy was designed to 
obtain as many sources as possible while ensuring that 
the sources were representative of the population at the 
national level or at least a ﬁ rst administrative unit within 
the country. We included data from the WHO Vitamin 
and Mineral Nutrition Information System 
Micronutrients Database,19 data reported by other 
agencies, and those in the published scientiﬁ c literature. 
Additional details about our data search, data access, 
inclusion criteria, ﬂ ow chart of data access, and data 
sources are in the appendix.
We used serum retinol concentration as an indicator of 
vitamin A deﬁ ciency because it is the most commonly 
used biomarker for assessment of subclinical vitamin A 
deﬁ ciency at the population level.19,20 Vitamin A deﬁ ciency 
was deﬁ ned as serum retinol concentrations lower than 
0·70 μmol/L. We did not use data for clinical indicators of 
vitamin A deﬁ ciency—namely, xerophthalmia (eg, night 
blindness, corneal scarring, and Bitot’s spots). We took 
this approach because night blindness and corneal 
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Research in context
Evidence before this study
We searched PubMed without date limits, using the search terms 
“vitamin A deﬁ ciency”, “trend” or “forecasting”, and “spatial” or 
“subnational”. No language restrictions were applied. 
Additionally to indexed articles, many such comparisons are in 
national and international agency reports, which we also 
identiﬁ ed and accessed through requests to national and 
international organisations. For the associations between 
vitamin A deﬁ ciency in children and cause-speciﬁ c mortality, we 
used a systematic review and the DEVTA trial, which has been 
published since the completion of that review. 
WHO has compiled data for vitamin A deﬁ ciency by country and 
used the data to make estimates of vitamin A deﬁ ciency 
worldwide and by region, at speciﬁ c points in time. Other 
researchers have also reported change across repeated surveys. 
Researchers, together with the UN Standing Committee on 
Nutrition, used a regression with time-varying covariates to 
analyse how vitamin A deﬁ ciency has changed in world regions. 
Studies have also estimated deaths attributable to vitamin A 
deﬁ ciency at one or two timepoints using data for prevalence 
and relative risks for the eﬀ ects of vitamin A deﬁ ciency on cause-
speciﬁ c mortality.
Added value of the study
Our study advances the international reporting and 
comparison of vitamin A deﬁ ciency and its mortality burden 
by compiling the latest surveillance data and estimation of 
trends in deﬁ ciency and burden by world region. We 
estimated that vitamin A deﬁ ciency was most prevalent in 
sub-Saharan Africa and south Asia, where there has been no 
evidence of a reduction in prevalence since 1991. By contrast, 
prevalence has decreased in east and southeast Asia and 
Oceania, and a decline in Latin America and the Caribbean 
might have also occurred. The absolute mortality burden of 
vitamin A deﬁ ciency has been more than halved since 2000 
alone, including major reductions in sub-Saharan Africa and 
south Asia.
Implications of all the available evidence
This new evidence on both prevalence and absolute burden of 
vitamin A deﬁ ciency should be used to reconsider, and possibly 
revise, priority countries for vitamin A supplementation. 
Improved data for vitamin A deﬁ ciency in high-prevalence 
regions are also needed.
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scarring are not usually measured in children younger 
than 2 years of age. We attempted to convert prevalence of 
Bitot’s spots, which is measured more commonly in 
children,19 to prevalence of low serum retinol concentration 
but the association between the two variables was weak 
and heterogeneous (appendix), and hence did not allow 
robust conversion. This might be because Bitot’s spots are 
sometimes associated with previous versus current 
vitamin A deﬁ ciency.21 Some surveys22 have used retinol-
binding protein as an indicator of vitamin A status instead 
of serum retinol because its measurement is less costly. 
However, we identiﬁ ed very few sources that had 
measured both serum retinol and retinol-binding protein 
and hence could not develop a statistical model to convert 
retinol-binding protein to serum retinol.
  We obtained RRs for the eﬀ ects of vitamin A deﬁ ciency 
on mortality from measles and diarrhoea from randomised 
trials of vitamin A supplementation (appendix). Most of 
these trials were summarised in systematic reviews and 
meta-analyses.1,2 The DEVTA trial3 has been published 
since these reviews were completed and was included 
here. Consistent with the conclusions of systematic 
reviews,1,2 we restricted the mortality eﬀ ects to ages 
6–59 months, the age range in which trials have collectively 
identiﬁ ed an eﬀ ect. The number of deaths in children 
aged 1–59 months by cause for 2000–13 was obtained 
from WHO and the Child Health Epidemiology Reference 
Group, with data sources and methods described in detail 
elsewhere.18 Following the analyses used in the Lancet 
Series on Maternal and Child Undernutrition published 
in 2013,14 we estimated that 79% of postneonatal child 
diarrhoea deaths occur in children aged 6–59 months,23 
and that all post-neonatal child measles deaths occur in 
children aged 6–59 months of age; this estimate is based 
on an analysis of verbal autopsy data by age group (Li Liu, 
John Hopkins University, personal communication). 
Statistical analysis
Nine (7%) of the 134 data sources reported mean serum 
retinol or prevalence of deﬁ ciency based on serum retinol 
concentrations less than 0·35 μmol/L or serum retinol 
concentrations less than 1·05 μmol/L (appendix). We 
used data sources that had reported both prevalence of 
serum retinol concentrations less than 0·70 μmol/L and 
any of the other three metrics to develop regression 
models to estimate serum retinol. This approach has 
been successfully used to convert between prevalence of 
diabetes, hypertension, or obesity and mean blood 
glucose, blood pressure, or body-mass index,24–26 and to 
convert between severity cutoﬀ s used to deﬁ ne blindness 
and impaired vision.27 We accounted for the additional 
uncertainty associated with this conversion by combining 
the regression uncertainty with that caused by sampling.
The statistical methods are described in detail in a 
previous publication.28 Brieﬂ y, we used a Bayesian 
hierarchical probit model, which uses all available data to 
make estimates for each country-year. In the hierarchical 
model, estimates for each country-year were informed by 
data from that country-year itself, if available, and by data 
from other years in the same country and in other 
countries, especially those in the same region with data 
from similar time periods. The hierarchical model shares 
information to a greater degree where data are non-existent 
or weakly informative (ie, have large uncertainty), and to a 
lesser degree in countries or regions and in years with 
more data. We modelled trends over time as a linear trend. 
We did not include a non-linear term, as done for stunting, 
underweight, or anaemia,28–30 because fewer countries had 
several data sources for vitamin A deﬁ ciency than for other 
nutritional indicators; this data scarcity limits robust 
estimation of non-linear trends. The estimates were also 
informed by covariates that might help to predict vitamin 
A deﬁ ciency at the population level, including national 
income (logarithm of per-person gross domestic product 
[GDP] in inﬂ ation-adjusted international dollars), maternal 
education, proportion of population that lived in urban 
areas, mean weight-for-age Z score, and an aggregate 
metric of availability of calories and animal-source foods.31,32 
The model included a variance term that accounted for 
unobserved design factors (sample design, season, retinol 
measurement method, etc) that led to variability in the 
data beyond that expected because of sample size. Finally, 
the model accounted for the fact that subnational data 
might have larger variation than national data by including 
an additional, empirically estimated, random eﬀ ect for 
subnational data.
The uncertainties of our estimates incorporate the 
sampling error in each data source; non-sampling error 
arising from issues in sample design and measurement 
that aﬀ ects the variability of reported prevalences; 
additional error associated with subnational data; 
uncertainty associated with converting from mean serum 
retinol, prevalence of serum retinol concentrations lower 
than 0·35 μmol/L, or prevalence of serum retinol 
concentrations lower than 1·05 μmol/L to the primary 
outcome; and uncertainty due to making estimates by 
country and year when data were missing.
We ﬁ tted the Bayesian model using the Markov chain 
Monte Carlo (MCMC) algorithm and obtained 
1000 samples of the model variables, which were used to 
obtain 1000 posterior samples of vitamin A deﬁ ciency for 
each country-year. Prevalences for regions and the world 
were calculated as population-weighted averages of those 
of the constituent countries. All reported credible intervals 
represent the 2·5th–97·5th percentiles of the MCMC 
draws. We report the posterior probability (PP) that an 
estimated increase or decrease in prevalence represents a 
truly decreasing trend. The PP would be 0·50 when a 
decrease is statistically indistinguishable from an increase, 
a PP larger than 0·50 indicates more certainty about a 
decreasing trend, and a PP smaller than 0·50 indicates 
more certainty about an increasing trend.
We obtained RRs for the association between vitamin A 
deﬁ ciency and cause-speciﬁ c mortality by pooling RRs of 
Articles
e531 www.thelancet.com/lancetgh   Vol 3   September 2015
randomised intervention studies. The participants of 
randomised vitamin A supplementation trials might be a 
mix of children who were vitamin A deﬁ cient and those 
who had adequate vitamin A intake. Supplementation 
beneﬁ ts the deﬁ cient participants to the extent that it 
compensates for inadequate dietary intake. For this 
reason, and following previous analyses of vitamin A 
deﬁ ciency and anaemia,12,33 we adjusted trial RRs for 
background prevalence of deﬁ ciency to calculate the 
reduction in risk in the deﬁ cient group (appendix). We 
used background prevalence in the trial participants 
when available, and the estimated national prevalence 
from our own analysis when the trial had not measured 
baseline serum retinol. We then pooled the adjusted RRs 
using a random-eﬀ ects model.34
We calculated the population attributable fraction (PAF), 
which is the proportional reduction in deaths from 
diarrhoea and measles that would occur if vitamin A 
deﬁ ciency had been eliminated.15 We calculated the 
number of deaths from diarrhoea and measles attributable 
to vitamin A deﬁ ciency by multiplying their corresponding 
PAF by total deaths from that disease. To calculate the 
uncertainties of the number of deaths attributable to 
vitamin A deﬁ ciency, we used 1000 draws from the 
uncertainty distributions of each input (prevalence, RR, 
and total number of cause-speciﬁ c deaths), and repeated 
the calculations using these draws. The resulting 
distribution characterised the uncertainty distributions of 
the number of deaths attributable to vitamin A deﬁ ciency.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. GAS and JEB had full access to the data. ME 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
We collated 134 population-representative data sources 
from 83 countries with measured serum retinol 
concentration data (appendix). Of these, 70 were from the 
1990s and 64 were from 2000 or later. 90 (67%) were 
nationally representative. 29 countries had two or more 
data sources, and 54 countries had only one data source. 
55 countries had no data (ﬁ gure 1). Because of limited 
availability and large within-region and within-country 
variations in measured prevalences, the estimated 
prevalences had large uncertainty compared with other 
risk factors,24–26,28,29,35 even at the regional level (table 1).
In 1991, 39% (95% credible interval [CrI] 27–52) of 
children in low-income and middle-income countries 
Figure 1: Number of data sources used in the analysis, by country
Excluded from analysis
No data
1 data source
≥2 data sources
Prevalence in 
1991 (%)
Prevalence in 
2000 (%)
Prevalence in 
2013 (%)
PP of 
decrease
Central Asia, Middle East, and north Africa 19% (5–40) 14% (7–23) 11% (2–27) 0·76
East and southeast Asia and Oceania 42% (19–70) 21% (14–30) 6% (1–16) 0·99
Latin America and the Caribbean 21% (11–33) 15% (10–22) 11% (4–23) 0·89
South Asia 47% (14–78) 46% (28–62) 44% (13–79) 0·54
Sub-Saharan Africa 45% (29–60) 49% (40–58) 48% (25–75) 0·45
All low-income and middle-income countries 39% (27–52) 33% (27–39) 29% (17–42) 0·81
Data are % (95% CrI), unless otherwise speciﬁ ed. Tabulations by WHO, UNICEF, and UN regions are presented in the 
appendix. A PP greater than 0·50 indicates a decrease and a PP smaller than 0·50 indicates an increase in deﬁ ciency. 
PP=posterior probability. CrI=credible interval.
Table 1: Estimated prevalence of vitamin A deﬁ ciency by region in 1991, 2000, and 2013, and the PP that 
the reported decrease is a true decrease
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were vitamin A deﬁ cient (table 1). Regional prevalences 
in 1991 ranged from more than 40% in sub-Saharan 
Africa, south Asia, and east and southeast Asia and 
Oceania, to less than 25% in Latin America and the 
Caribbean, and in the region of central Asia, the Middle 
East, and north Africa. Nationally, the prevalence of 
vitamin A deﬁ ciency was at least 8% in every country; 
100 countries had a prevalence of at least 20%, and 
hence would be classiﬁ ed as having a public health 
problem by WHO. 
Trends in the prevalence of deﬁ ciency from 1991 to 
2013 varied by region, with a slight improvement at the 
worldwide level to 29% (17–42; PP of being a true 
decline=0·81). Deﬁ ciency signiﬁ cantly decreased in only 
one region: east and southeast Asia and Oceania, from 
42% (19–70) to 6% (1–16; PP=0·99). The prevalence of 
deﬁ ciency might have decreased in Latin America and 
the Caribbean to 11% (4–23) in 2013 (PP=0·89) and in 
central Asia, Middle East, and north Africa to 11% (2–27) 
in 2013 (PP=0·76). In sub-Saharan Africa and south Asia, 
little change in prevalence occurred during the analysis 
period; both regions had prevalences of more than 40% 
for all years during the analysis period.
The prevalence of vitamin A deﬁ ciency decreased by 
more than 20 percentage points in 24 countries: 23 of 
these countries were in east and southeast Asia and 
Oceania and one was in sub-Saharan Africa; the PPs for 
declines in these countries ranged between 0·86 and 
greater than 0·99 (ﬁ gure 2). Many countries in south 
Asia and sub-Saharan Africa had no improvement and 
some might even have had a deterioration in vitamin A 
status during this period. By 2013, the prevalence of 
vitamin A deﬁ ciency was between 3% and 9% in 
47 countries: 21 in Latin America and the Caribbean, 
12 in east and southeast Asia and Oceania, and 14 in 
central Asia, north Africa, and the Middle East (ﬁ gure 3). 
Prevalence was 20% or higher in 56 countries, and was 
more than 40% in three south Asian and 40 African 
countries.
In the pooled analysis of randomised trials, vitamin A 
supplementation was associated with a 24% (95% CI 
7–38) reduction in the risk of dying from diarrhoea and a 
14% (−8 to 32) reduction in the risk of dying from measles 
(appendix). After adjustment for background prevalences, 
being vitamin A deﬁ cient was associated with a RR of 
1·69 (1·17–2·45) for death from diarrhoea and 1·26 
(0·84–1·87) for death from measles. 
94 500 (95% CrI 54 200–146 800) deaths from diarrhoea 
and 11 200 (4300–20 500) deaths from measles were 
attributable to vitamin A deﬁ ciency in 2013 (table 2). 
These ﬁ gures amount to 1·7% (1·0–2·6) of all deaths in 
children younger than 5 years in low-income and middle-
income countries. The number of deaths attributable to 
vitamin A deﬁ ciency in 2013 was less than half of those 
in 2000, when the number of attributable deaths was 
266 200 (188 800–334  700). By comparison, the share of 
deaths in children younger than 5 years attributable to 
this deﬁ ciency was somewhat similar in the two periods: 
2·7% (1·9–3·5) in 2000 and 1·7% (1·0–2·6) in 2013. In 
view of the fact that little reduction occurred in the 
prevalence of deﬁ ciency in the highest-burden regions 
(south Asia and sub-Saharan Africa), the worldwide 
decrease in vitamin-A-deﬁ ciency-attributable deaths was 
mainly due to reduced deaths from diarrhoea and 
>80%
70–80%
60–70%
50–60%
40–50%
30–40%
20–30%
<20%
No estimate made
Probable VAD
decrease
Probable VAD
increase
Figure 2: The posterior probability that vitamin A deﬁ ciency decreased from 1991 to 2013
VAD=vitamin A deﬁ ciency.
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measles in south Asia and sub-Saharan Africa. In 2013, 
more than 95% of deaths attributable to vitamin A 
deﬁ ciency occurred in sub-Saharan Africa and south 
Asia, where both the prevalence of deﬁ ciency and child 
mortality are high. In these regions, vitamin A deﬁ ciency 
accounted for 2·0% (1·0–3·4) of all deaths in children 
younger than 5 years in sub-Saharan Africa and 2·0% 
(0·7–3·5) of all deaths in children younger than 5 years 
in south Asia.
Discussion
Our estimates of the prevalence of vitamin A deﬁ ciency 
in developing countries using population-based data 
suggest that deﬁ ciency is highest in south Asia and sub-
Saharan Africa, where our results indicate little change 
during the past two decades; however, our estimates are 
very uncertain because of data limitations. We noted 
evidence of improvement in east and southeast Asia and 
Oceania, and suggestion of improvement in Latin 
Figure 3: Estimated prevalence of vitamin A deﬁ ciency in children aged 6 to 59 months by country in 2013 (A) and the posterior standard deviation 
(analogous to standard error in non-Bayesian analysis) of the estimates (B)
A
B
<10%
10–19%
20–39%
40–59%
≥60%
No estimate made 
4–9%
10–14%
15–19%
20–26%
No estimate made
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America and the Caribbean and central Asia, the Middle 
East, and north Africa. The persistent high prevalence of 
vitamin A deﬁ ciency in south Asia and sub-Saharan 
Africa might be due to insuﬃ  cient dietary diversiﬁ cation, 
unsuccessful food fortiﬁ cation, and the restricted eﬀ ect 
of vitamin A capsule delivery on serum retinol. Frequent 
exposure to infections,23 which increase the risk of 
subclinical deﬁ ciency and decrease serum retinol 
concentrations in children with adequate liver stores,36 
might have also contributed to persistent vitamin A 
deﬁ ciency in regions with high infection burden.
The number of deaths attributable to vitamin A 
deﬁ ciency, about 100 000, was substantially smaller than 
the mortality eﬀ ects of suboptimal growth,14 which 
increases the risk of dying from a range of infectious 
diseases.37 Nonetheless, in the two worst-oﬀ  regions of 
south Asia and sub-Saharan Africa, vitamin A deﬁ ciency 
accounted for around 2% of child deaths. The number of 
deaths attributable to this risk factor has decreased by 
more than 50% since 2000, mainly because child deaths 
from diarrhoea and measles have declined. These 
decreases are probably because of improvements in 
general nutritional status and water and sanitation (for 
diarrhoea),23 and vaccinations (for measles),38 although 
vitamin A supplementation might have played a part.
Our estimated prevalence for the year 2000 of 33% 
(95% CrI 27–39) in 138 low-income and middle-income 
countries coincides with the 33% (31–35) reported by the 
WHO for 1995–2005 in countries with a 2005 GDP per 
person of less than or equal to US$15 000.7 Our CrIs also 
overlap with estimates published by the UN Standing 
Committee on Nutrition, as do our estimates of a moderate 
decline in deﬁ ciency since 1990 worldwide.9 The number 
of deaths attributable to vitamin A deﬁ ciency is also 
consistent with the 120 000–160 000 deaths estimated in 
the GBD 2010 study16 and in the Lancet Series on Maternal 
and Child Undernutrition.14 All these estimates are 
substantially lower than those of the Comparative Risk 
Assessment Study12 and the Lancet Series on Maternal and 
Child Undernutrition published in 2008.13 This downward 
adjustment occurred because trials led to the exclusion of 
malaria as an outcome of vitamin A deﬁ ciency, lowering 
of RRs for other outcomes, and changing the age range of 
analysis from 1–59 months to 6–59 months. Had we only 
used the trials included in the 2010 Cochrane systematic 
review1 (ie, excluding the large DEVTA trial which had 
somewhat small eﬀ ects),2,39 the number of deaths 
attributable to vitamin A deﬁ ciency in children aged 
6–59 months would be about 50% higher than presented. 
In relation to age group, trial evidence does not collectively 
provide evidence of eﬀ ects in infants younger than 
6 months of age.14,40–43
The strengths of our study are our extensive data search 
and rigorous criteria for inclusion of sources; estimation 
of trends; and systematic estimation and reporting of 
uncertainty to show the extent of data scarcity. The main 
Diarrhoea Measles All causes
Number (in 
thousands) 
Proportion of all 
deaths (%)
Number (in 
thousands) 
Proportion of all 
deaths (%)
Number (in 
thousands) 
Proportion of all 
deaths (%)
2000
Central Asia, Middle East, and 
north Africa
3·7 (1·6–5·9) 8·2% (3·7–13·3) 0·4 (0·0–0·9) 5·0% (0·8–12·3) 4·1 (1·8–6·5) 0·9% (0·4–1·4)
East and southeast Asia and 
Oceania
11·5 (7·1–17·6) 10·5% (6·7–15·5) 2·3 (0·5–4·8) 7·2% (1·9–16·2) 13·9 (8·5–20·6) 1·2% (0·7–1·7)
Latin America and the 
Caribbean
2·5 (1·4–3·8) 7·6% (4·5–11·7) 0 NA* 2·5 (1·4–3·8) 0·6% (0·4–1·0)
South Asia 90·9 (40·9–143·3) 18·0% (8·4–28·3) 12·3 (1·9–24·6) 11·2% (1·9–24·7) 103·2 (49·1–156·7) 3·0% (1·4–4·6)
Sub-Saharan Africa 102·8 (69·9–142·8) 19·0% (15·0–23·7) 39·7 (14·1–66·2) 11·5% (5·1–21·1) 142·5 (96·2–189·4) 3·4% (2·3–4·5)
All low-income and 
middle-income countries
211·4 (147·6–279·0) 17·2% (12·7–21·6) 54·8 (24·0–85·0) 11·0% (5·8–18·4) 266·2 (188·8–334·7) 2·7% (1·9–3·5)
2013
Central Asia, Middle East, and 
north Africa
1·2 (0·2–2·8) 6·5% (1·4–14·7) 0·0 (0·0–0·1) 4·3% (0·3–16·6) 1·2 (0·2–2·9) 0·4% (0·1–0·9)
East and southeast Asia and 
Oceania
1·4 (0·4–3·2) 4·1% (1·1–9·0) 0·2 (0·0–0·6) 2·0% (0·3–6·0) 1·6 (0·4–3·6) 0·3% (0·1–0·6)
Latin America and the 
Caribbean
0·5 (0·2–1·1) 5·9% (1·9–11·9) 0 NA* 0·5 (0·2–1·1) 0·3% (0·1–0·5)
South Asia 34·8 (11·1–61·7) 17·0% (5·8–31·0) 5·1 (0·5–13·6) 11·1% (1·2–30·1) 39·9 (13·0–69·2) 2·0% (0·7–3·5)
Sub-Saharan Africa 56·6 (28·7–100·6) 18·4% (10·5–26·6) 5·9 (2·2–11·0) 13·0% (4·8–23·8) 62·5 (32·9–107·0) 2·0% (1·0–3·4)
All low-income and 
middle-income countries
94·5 (54·2–146·8) 16·5% (10·1–23·4) 11·2 (4·3–20·5) 11·0% (4·3–20·2) 105·7 (60·8–163·7) 1·7% (1·0–2·6)
Data in parentheses are 95% CrI. Tabulations by WHO, UNICEF, and UN regions are presented in the appendix. CrI=credible interval. NA=not available. *A population 
attributable fraction was not calculated because no measles deaths occurred in the Latin America and Caribbean region during this time period. 
Table 2: Number (in thousands) and proportion (%) of child deaths attributable to vitamin A deﬁ ciency by region in 2000 and 2013
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limitation of our analysis is that, despite the extensive 
data search and access, fewer data were available for 
biological markers of vitamin A deﬁ ciency than for other 
nutritional conditions, including anthropometric status 
and anaemia,28,29 which are easier to measure in 
population-based surveys. Data shortage was exacerbated 
by the fact that it was not possible to predict the prevalence 
of deﬁ ciency on the basis of serum retinol from the more 
recently available retinol-binding protein data; 
nonetheless, some recent surveys with serum retinol 
were accessed and used in the analysis. In regions where 
deﬁ ciency remains prevalent, speciﬁ cally south Asia and 
sub-Saharan Africa, investment in surveillance using 
consistent methods would help provide improved 
information for both intervention priorities and to assess 
the eﬀ ects of programmes and overall changes in 
nutrition on the prevalence of deﬁ ciency. We did not 
estimate the prevalence of vitamin A deﬁ ciency in women 
of reproductive age and in children younger than 
6 months of age because the pooled eﬀ ect of randomised 
trials of maternal vitamin A supplementation does not 
suggest beneﬁ t in terms of reduction of maternal 
mortality or mortality before 6 months of age.1,2,44 However, 
night blindness caused by deﬁ ciency might be a source of 
disability in women. Finally, cross-sectional health and 
nutrition surveys do not allow establishment of whether 
low serum retinol is due to insuﬃ  cient intake or due to 
the temporary eﬀ ects of infection and accompanying 
inﬂ ammatory response; because deﬁ cient children are 
more at risk of infection, decoupling the role of the two 
factors can only be done in trial and longitudinal data. 
Further research is needed to establish a standard method 
for adjusting serum retinol measurements for those with 
increased acute-phase reactants.
The large reductions in child mortality in initial trials of 
vitamin A supplementation led to eﬀ orts to scale up high 
dose vitamin A supplementation in low-income and 
middle-income countries, despite some controversy about 
how large the beneﬁ ts of these programmes might be.45–47 
According to UNICEF’s summary of administrative data,5 
more than two-thirds of children in the developing world 
now receive vitamin A supplementation, with most 
receiving the recommended two annual doses; in the late 
1990s, only half received any supplementation and less 
than 20% received two doses per year.5 Despite these 
eﬀ orts, the prevalence of vitamin A deﬁ ciency does not 
seem to have changed in these regions. The persistently 
high levels of deﬁ ciency might be because 
supplementation, by contrast with regular dietary intake, 
increases serum retinol over short periods of 8 to 
12 weeks,48 although sparseness of data might also have 
made it diﬃ  cult to spot their eﬀ ects. Supplementation 
nonetheless might have contributed to mortality reduction 
based on the results of randomised trials.1–3,39 At the same 
time, we have noted downward revisions of the mortality 
burden of vitamin A deﬁ ciency with the most detailed and 
up-to-date analysis presented in this paper.
The reported trends in the prevalence and the mortality 
burden in diﬀ erent regions have two implications. The 
ﬁ rst is that improvement of vitamin A status in south 
Asia and sub-Saharan Africa to replicate the reductions 
in deﬁ ciency seen in east and southeast Asia and in Latin 
America and the Caribbean will probably need an 
improvement in the overall nutrition of the population, 
including through dietary diversiﬁ cation and improved 
access to vitamin-rich foods, and improved access to 
treatment for infectious diseases. Until this happens, 
large scale or targeted supplementation or fortiﬁ cation 
strategies will probably have some beneﬁ cial eﬀ ect on 
mortality in these regions.47 Data to identify subnational 
populations at risk of vitamin A deﬁ ciency are also 
needed to guide targeting of interventions in a more 
eﬀ ective way. The second implication is that 
supplementation needs in east and southeast Asia and in 
Latin America and the Caribbean, where the prevalence 
of deﬁ ciency and child mortality are both quite low 
compared with south Asia and sub-Saharan Africa, 
should be reconsidered, possibly leading to a revised and 
shorter list of priority countries.
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